Table 1.
Demographic and clinical characteristics of patient population
| Characteristic | Patient data (n = 93) |
|---|---|
| Male sex, n (%) | 41 (44) |
| BMI, mean kg/m2 (SD) | 32.8 (7.8) |
| Age, mean y (SD) | 53.2 (14.6) |
| Premedication administered, n (%) | 85 (91.4) |
| Acetaminophen, n (%) | 85 (91.4) |
| Diphenhydramine, n (%) | 0 (0) |
| High risk factors for severe or worsening disease | |
| Age ≥ 65, n (%) | 21 (22.6) |
| BMI > 25, n (%) | 83 (89.2) |
| CKD, n (%) | 3 (3.2) |
| DM, n (%) | 14 (15.1) |
| Immunosuppressive treatment, n (%) | 2 (2.2) |
| Immunosuppressive disease, n (%) | 3 (3.2) |
| CV or HTN, n (%) | 36 (38.7) |
| Lung disease, n (%) | 15 (16.1) |
| Time since COVID-19 symptom onset, mean d (SD) | 5.7 (2.8) |
| Time since COVID-19 positive test, mean d (SD) | 3.4 (2.9) |
| Patient reported COVID-19 vaccine status | |
| Unvaccinated, n (%) | 43 (46.2) |
| Not reported, n (%) | 5 (5.4) |
| Pfizer, n (%) | 24 (25.8) |
| Moderna, n (%) | 12 (12.9) |
| Johnson and Johnson, n (%) | 6 (6.5) |
| Vaccinated but type unreported, n (%) | 3 (3.2) |
| Average time to phone call follow-up, d (SD) | 36.1 (25.9) |
Abbreviations used: BMI, body mass index; CKD, chronic kidney disease; DM, diabetes mellitus, CV, cardiovascular; HTN, hypertension.
Note: Body mass index is the weight in kilograms divided by the square of the height in meters.